Search

Your search keyword '"CDG, Congenital disorders of glycosylation"' showing total 2 results
Start Over Descriptor "CDG, Congenital disorders of glycosylation" Journal molecular genetics and metabolism reports
2 results on '"CDG, Congenital disorders of glycosylation"'

1. Acetazolamide treatment in late onset CDG type 1 due to biallelic pathogenic DHDDS variants.

Author

Mousa J, Veres L, Mohamed A, De Graef D, and Morava E

Abstract

Pathogenic variants in DHDDS have been associated with either autosomal recessive retinitis pigmentosa or DHDDS-CDG. Heterozygous variants in DHDDS have been described in patients with a progressive neurodegenerative disease. Here we report on an individual presenting with a multisystem CDG phenotype who was diagnosed with known homozygous pathogenic DHDDS variants, previously associated with isolated retinitis pigmentosa. An adult Ashkenazi Jewish female developed multiple symptoms of late onset type 1 CDG including seizures, ataxia, protein losing enteropathy, tremor, and titubation in association with elevated mono-oligo/di-oligo transferrin ratio in blood, and classic retinitis pigmentosa. She was diagnosed by whole exome sequencing with the common Ashkenazi Jewish, homozygous p.K42E variants in DHDDS. She was started on Acetazolamide and responded well to the treatment which improved her titubation, tremor, and generalized edema. Reviewing the literature, families with DHDDS variants and multisystem presentation were different from our patient's presentation in terms of clinical manifestations, severity, genetic defect, and mode of inheritance. In previously reported patients with neurologic symptoms including seizures, movement abnormalities, and global development delay, the phenotype was caused by heterozygous pathogenic variants in DHDDS . The infant who was reported with a multisystem phenotype and fatal type 1 CDG had compound heterozygosity for a nonsense and a splice site variant in DHDDS, resulting in DHDDS-CDG. The discovery of the novel phenotype associated with the common p.K42E pathogenic variant in DHDDS expands the spectrum of CDG and further enhances our understanding on the role of DHDDS in glycosylation beyond the retina., (© 2022 The Authors.)

Published
2022
Full Text
View/download PDF

2. Global serum glycoform profiling for the investigation of dystroglycanopathies & Congenital Disorders of Glycosylation

Author

Heywood, Wendy E., Bliss, Emily, Mills, Philippa, Yuzugulen, Jale, Carreno, Gabriela, Clayton, Peter T., Muntoni, Francesco, Worthington, Viki C., Torelli, Silvia, Sebire, Neil J., Mills, Kevin, and Grunewald, Stephanie

Subjects
lcsh:R5-920, congenital, hereditary, and neonatal diseases and abnormalities, CDG, Congenital Disorders of Glycosylation, TFN, transferrin, MD, muscular dystrophy, MW, molecular weight, IEF, isoelectric focusing, Dystroglycanopathies, 2D DIGE, α1-Antitrypsin, 2D DIGE, 2-dimensional differential gel expression, Congenital Disorders of Glycosylation, lcsh:Biology (General), Glycoproteome, COG, conserved oligomeric golgi, lcsh:Medicine (General), lcsh:QH301-705.5, Research Paper, C1-esterase inhibitor
Abstract

The Congenital Disorders of Glycosylation (CDG) are an expanding group of genetic disorders which encompass a spectrum of glycosylation defects of protein and lipids, including N- & O-linked defects and among the latter are the muscular dystroglycanopathies (MD). Initial screening of CDG is usually based on the investigation of the glycoproteins transferrin, and/or apolipoprotein CIII. These biomarkers do not always detect complex or subtle defects present in older patients, therefore there is a need to investigate additional glycoproteins in some cases. We describe a sensitive 2D-Differential Gel Electrophoresis (DIGE) method that provides a global analysis of the serum glycoproteome. Patient samples from PMM2-CDG (n = 5), CDG-II (n = 7), MD and known complex N- & O-linked glycosylation defects (n = 3) were analysed by 2D DIGE. Using this technique we demonstrated characteristic changes in mass and charge in PMM2-CDG and in charge in CDG-II for α1-antitrypsin, α1-antichymotrypsin, α2-HS-glycoprotein, ceruloplasmin, and α1-acid glycoproteins 1&2. Analysis of the samples with known N- & O-linked defects identified a lower molecular weight glycoform of C1-esterase inhibitor that was not observed in the N-linked glycosylation disorders indicating the change is likely due to affected O-glycosylation. In addition, we could identify abnormal serum glycoproteins in LARGE and B3GALNT2-deficient muscular dystrophies. The results demonstrate that the glycoform pattern is varied for some CDG patients not all glycoproteins are consistently affected and analysis of more than one protein in complex cases is warranted. 2D DIGE is an ideal method to investigate the global glycoproteome and is a potentially powerful tool and secondary test for aiding the complex diagnosis and sub classification of CDG. The technique has further potential in monitoring patients for future treatment strategies. In an era of shifting emphasis from gel- to mass-spectral based proteomics techniques, we demonstrate that 2D-DIGE remains a powerful method for studying global changes in post-translational modifications of proteins.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results